WO2011031827A2 - Fabrication de produits de matrice extracellulaire à l'aide de fluides supercritiques ou quasi-supercritiques - Google Patents

Fabrication de produits de matrice extracellulaire à l'aide de fluides supercritiques ou quasi-supercritiques Download PDF

Info

Publication number
WO2011031827A2
WO2011031827A2 PCT/US2010/048223 US2010048223W WO2011031827A2 WO 2011031827 A2 WO2011031827 A2 WO 2011031827A2 US 2010048223 W US2010048223 W US 2010048223W WO 2011031827 A2 WO2011031827 A2 WO 2011031827A2
Authority
WO
WIPO (PCT)
Prior art keywords
extracellular matrix
endogenous
matrix material
ecm
bioactive components
Prior art date
Application number
PCT/US2010/048223
Other languages
English (en)
Other versions
WO2011031827A3 (fr
Inventor
Jian-Lin Liu
Bruce J. Demars
Bhavin Shah
Original Assignee
Cook Biotech Incorporated
Sabin Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook Biotech Incorporated, Sabin Corporation filed Critical Cook Biotech Incorporated
Publication of WO2011031827A2 publication Critical patent/WO2011031827A2/fr
Publication of WO2011031827A3 publication Critical patent/WO2011031827A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Definitions

  • aspects of the present invention relate to products containing extracellular matrix materials obtained from animal sources, and to processes for their manufacture and use.
  • the present invention relates to methods for processing animal-derived extracellular matrix materials using fluid at or near supercritical conditions and to products with unique mechanical, biochemical, and bioperformance properties that are obtainable by such methods.
  • ECM extracellular matrix
  • medical grafts and cell culture materials containing submucosa derived from small intestine, stomach or urinary bladder tissues have been proposed. See, e.g., U.S. Patent Nos. 4,902,508, 4,956, 178, 5,281 ,422, 5,554,389, 6,099,567 and 6,206,931 .
  • Cook Biotech Incorporated, West Lafayette, Indiana currently manufactures a variety of medical materials based upon small intestinal submucosa under the trademarks SURGISIS®, STRATASIS® and OASIS®.
  • One feature of the present invention is the discovery that animal- derived extracellular matrix (ECM) materials can be processed with a supercritical fluid or near supercritical fluid to purify the materials while beneficially retaining both bioactivity and mechanical performance properties.
  • ECM animal- derived extracellular matrix
  • the invention provides methods for making ECM products that include the steps of treating a collagenous ECM material retaining one or more endogenous bioactive components with an at least substantially supercritical fluid, and thereafter recovering the treated collagenous ECM material still retaining an amount of the one or more endogenous bioactive components.
  • the one or more endogenous bioactive components can include at least one of an endogenous growth factor, an endogenous glycosaminoglycan, and an endogenous glycoprotein, and in preferred embodiments the treated collagenous ECM material includes a combination of all of these biomolecules.
  • the treatment with the near supercritical fluid or supercritical fluid can be effective to remove undesired components of the ECM material, for example endogenous lipids.
  • the ECM can be processed with one or more additional mediums, before and/or after treatment with the near/supercritical fluid, that enhance the biocompatibility of the finished ECM product.
  • the ECM can be treated with a decellularization medium separate from the near/supercritical fluid, preferably before treatment of the ECM with the near/supercritical fluid.
  • the decellularization medium can be a peracetic acid medium in certain embodiments.
  • a near/supercritical-fluid-treated ECM retaining the endogenous bioactive component(s) can be medically packaged and terminally sterilized to provide a medical product. Additional embodiments of the invention relate to other defined treatments of ECM materials with a near/supercritical fluid, and to ECM materials with enhanced properties and packaged end products that can, for example, be obtained by methods described herein.
  • FIG. 1 is a digital image illustrating capillary development upon implantation with a collagenous extracellular matrix material (small intestine submucosa, SIS) that retains endogenous bioactive components.
  • SIS collagenous extracellular matrix material
  • FIG. 2 is a digital image illustrating capillary development upon implantation with a collagenous extracellular matrix material (SIS) that has been processed in such a fashion as to eliminate endogenous bioactive components.
  • SIS collagenous extracellular matrix material
  • aspects of the present invention relate to the use of a supercritical or near supercritical fluid in the manufacture of useful extracellular matrix (ECM) materials. Additional embodiments of the invention relate to uniquely characterized ECM materials and their use in medical applications in humans or non-human animals.
  • ECM extracellular matrix
  • Supercritical with reference to a fluid in general or to a specific compound, refers to such fluid or such compound at or above its critical temperature and at or above its critical pressure.
  • Near supercritical with reference to a fluid in general or to a specific compound, refers to such fluid or such compound that is not supercritical but which is at about 95% or more of its critical temperature and at about 95% or more of its critical pressure.
  • At least substantially supercritical with reference to a fluid in general or to a specific compound, refers to such fluid or such compound which is near supercritical or supercritical.
  • Near/supercritical is an abbreviation used at times herein referring to near supercritical or supercritical.
  • Subcritical with reference to a fluid in general or to a specific compound, refers to such fluid or such compound which is not supercritical.
  • Decellularizing refers to eliminating all or essentially all living endogenous cells from a tissue material, such as an ECM. "Decellularized”, with reference to a tissue material such as an ECM, means free or essentially free from living endogenous cells.
  • Acellular with reference to a tissue material such as an ECM, means free or essentially free from any living cells.
  • substantially devoid of cells and cell components means free or essentially free from cells (living or dead) and of cell membranes and other cell remnants.
  • An ECM material substantially devoid of cells or cell components is intended to include the ECM material carrying cells or cell components at a level sufficiently low to be substantially nonimmunogenic when the material is implanted in a recipient, especially a recipient to which the cells or cell components are xenogenic or allogenic.
  • Endogenous bioactive component refers to a bioactive substance that occurs endogenously with the ECM.
  • Bioactive in this context refers to the ability of a substance to induce, directly or indirectly, a cellular response such as a change in cell morphology, proliferation, growth, protein or gene expression.
  • endogenous lipids are not considered to be endogenous bioactive components.
  • suitable ECMs include collagenous ECM sheet materials comprising submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane layers, including liver basement membrane.
  • Suitable submucosa materials include, for instance, intestinal submucosa, including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa.
  • Suitable animal sources for the ECM materials include either human donors (e.g. cadavers) or non-human animals such as ovine, bovine or porcine animals.
  • Porcine ECM tissues are preferred.
  • ECM tissues that exist as, and that as isolated provide, thin membranous connective tissue sheets, e.g. sheets having a thickness of less than about 1000 ⁇ , more preferably less than about 500 ⁇ , are preferred.
  • FIGs. 1 and 2 provide a comparison of the performance of differentially processed ECM segments (both porcine SIS) upon implant.
  • FIG. 1 provides a digital image showing capillary ingrowth into a bioactive SIS material (retaining a substantially preserved microarchitecture including endogenous FGF-2 and other growth factors, endogenous glycosaminoglycans and endogenous proteoglycans) 21 days after implant.
  • the SIS material of FIG. 1 provides a digital image showing capillary ingrowth into a bioactive SIS material (retaining a substantially preserved microarchitecture including endogenous FGF-2 and other growth factors, endogenous glycosaminoglycans and endogenous proteoglycans) 21 days after implant.
  • SIS tissue including the tunica submucosa, muscularis mucosa, and stratum compactum
  • a segment of this SIS was used in a subcutaneous implant model in which 1 .5 cm-diameter discs were sandwiched between 0.22 ⁇ filters and implanted subcutaneously in mice. The filters resist through-growth of tissue and thus new tissue development can be observed growing into the edges of the sandwiched SIS samples.
  • mice were injected with fluorescent microbeads, which are then allowed to circulate. Images were then taken with confocal microscopy. As seen in FIG. 1 , capillary infiltration into the SIS was profuse and continued deep into the SIS layer.
  • 4-layer SIS samples prepared as described for FIG. 1 above and further chemically stripped (using strong sodium hydroxide) of essentially all components except collagen and a minor amount of elastin were subjected to similar subcutaneous implant testing and similarly imaged at 21 days.
  • FIG. 2 shows the results. As is evident, capillary growth into the stripped SIS is highly stunted relative to that observed in the inductive angiogenic SIS.
  • FIGs. 1 and 2 thus demonstrate that mild treatments in the preparation of ECM products can result in beneficially bioactive angiogenic materials, whereas even relatively brief treatments with harsher extractants are shown to disrupt the enhanced bioactive angiogenic character of the ECM.
  • endogenously bioactive ECM starting materials can be treated with near/supercritical fluids, well-recognized aggressive penetrating media with high solvent power, and nonetheless beneficially retain endogenous bioactive components giving them a bioactive character.
  • endogenously bioactive ECM materials were treated with supercritical carbon dioxide for two hours.
  • the resultant treated ECM materials retained substantially the same levels of endogenous FGF-2 and sulfated glycosaminoglycans as the starting ECM materials, whereas the endogenous lipid content of the treated ECM materials was substantially reduced.
  • the supercritical fluid treatment of the ECM materials did not significantly alter their tensile strength as compared to non-treated controls.
  • Near/supercritical fluid treatment of an endogenously bioactive ECM starting material can thus be used to process the material, for instance to reduce lipid content, while substantially retaining the endogenous bioactivity and mechanical properties of the ECM material such as high strength and/or excellent porosity.
  • ECM materials of and treated in accordance with the invention will include abundant collagen, most commonly being constituted at least about 80% by weight collagen on a dry weight basis.
  • Such ECM materials can include collagen fibers that are non-randomly oriented, for instance occurring as generally uniaxial or multi-axial but regularly oriented fibers.
  • the ECM material can retain these components interspersed as solids between, upon and/or within the collagen fibers.
  • Particularly desirable ECM materials for use in the invention will include significant amounts of such interspersed, non-collagenous bioactive component solids that are readily ascertainable under light microscopic examination (with appropriate staining).
  • non-collagenous solids can constitute a significant percentage of the dry weight of the ECM material in certain inventive embodiments, for example at least about 1 %, at least about 3%, and at least about 5% by weight in some embodiments of the invention.
  • the above- described collagen fiber orientations and/or levels of non-collagenous bioactive component solids can be present both before and after near/supercritical fluid treatment as described herein, and in final products.
  • the ECM material, both before and after the near/supercritical fluid treatment may also exhibit the ability to induce angiogenesis in a host engrafted with the material.
  • Angiogenesis is the process through which the body makes new blood vessels to generate increased blood supply to tissues.
  • angiogenic materials when contacted with host tissues, promote or encourage the formation of new blood vessels.
  • the ECM material both before and after the near/supercritical fluid treatment, can be fully bioremodelable.
  • "Fully bioremodelable" as used herein with reference to an ECM material means that the ECM material is effective upon implant in an animal subject (including a human) to promote cellular invasion and ingrowth during a time in which the originally implanted ECM material is eliminated, such that the originally implanted ECM material is replaced by tissue of the host.
  • the ECM material can retain any of a variety of growth factors or other beneficial bioactive components endogenous or native to the source tissue, both before and after processing with the near/supercritical fluid.
  • the ECM material can include one or more native growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF) and/or platelet derived growth factor (PDGF).
  • FGF-2 basic fibroblast growth factor
  • TGF-beta transforming growth factor beta
  • EGF epidermal growth factor
  • CTGF connective tissue growth factor
  • VEGF vascular endothelial growth factor
  • PDGF platelet derived growth factor
  • the ECM material can include other bioactive materials such as proteoglycans and/or sulfated glycosaminoglycans (sGAG), such as heparin sulfate, hyaluronic acid (HA), fibronectin and the like.
  • sGAG sulfated glycosaminoglycans
  • HA hyaluronic acid
  • fibronectin fibronectin and the like.
  • the ECM material both before and after the near/supercritical fluid treatment, will exhibit a component profile wherein the following non-collagen bioactive endogenous components are present in the stated amounts:
  • the ECM material will have an endogenous lipid content of less than about 4% by weight.
  • a final, sterile ECM product ready for implantation, and optionally suitably packaged, can also include the endogenous FGF-2, HA, sGAG and/or endogenous lipids in the above-stated amounts.
  • Compounds with critical temperatures less than about 60 5 C will be used with preference in generating the near/supercritical fluid used to treat the ECM materials.
  • Compounds with critical temperatures in the range of about 0 5 C to about 60 5 C will typically be used, more preferably with critical temperatures in the range of about 0 5 C to about 50 5 C.
  • the near/supercritical fluid treatment of the ECM material will desirably be conducted at a temperature at which no significant thermal damage occurs to the connective tissue (e.g. collagen) matrix of the ECM material, e.g. below the shrink temperature of a collagenous ECM material to be treated.
  • the near/supercritical fluid can be maintained at a temperature less than about 60 5 C during contact with the ECM material, typically in the range of about 0 5 C to about 60 5 C, and more preferably in the range of about 0 5 C to about 50 5 C.
  • the pressure of the near/supercritical fluid during treatment of the ECM material will depend upon the temperature used and the specific compound(s) used to generate the fluid, but in typical embodiments will range from about 500 pounds per square inch (psi) to about 5000 psi.
  • psi pounds per square inch
  • a variety of near/supercritical fluids can be used. Compounds which are gases under ambient conditions are useful for generating the near/supercritical fluids.
  • the treatment medium consists or consists essentially of near/supercritical carbon dioxide.
  • the ECM material can be treated with a pure near/supercritical fluid as a single near/supercritical substance or a mixture of near/supercritical substances, or with a near/supercritical fluid mixed with another component to facilitate the treatment, such as: a diluent; an entrainer; a surfactant; a detergent; an alcohol such as ethanol or n-propanol; a ketone such as acetone; an ester; dimethylsulfoxide (DMSO); dimethylformamide (DMF); a hydrocarbon; a disinfectant, for instance an oxidizing agent disinfectant such as hydrogen peroxide or an organic peroxy compound, more preferably a peracid such as peracetic acid, perpropioic acid, or perbenzoic acid; a chelating agent such as ethylene diamine tetraacetic acid (EDTA); an acidic aqueous medium (e.g.
  • the near/supercritical fluid treatment can be conducted to remove nucleic acid components, in which case the near/supercritical fluid can be mixed with a nucleic acid solubilizing medium such as a basic aqueous medium having a pH of above 7 to about 9, more preferably of about 8 to 8.5, desirably also including a biocompatible buffer such as tris(hydroxymethyl)aminomethane (TRIS) and a chelating agent such as (EDTA).
  • a nucleic acid solubilizing medium such as a basic aqueous medium having a pH of above 7 to about 9, more preferably of about 8 to 8.5, desirably also including a biocompatible buffer such as tris(hydroxymethyl)aminomethane (TRIS) and a chelating agent such as (EDTA).
  • TIS tris(hydroxymethyl)aminomethane
  • EDTA chelating agent
  • the near/supercritical fluid treatment can be conducted so as to sterilize the ECM material, an in such cases the presence of a disinfectant as noted above can assist in achieving sterility.
  • an ECM material can be sequentially contacted with different near/supercritical fluid mediums designed to enhance removal of different undesired components of the ECM material.
  • the ECM material can be contacted with a first near/supercritical fluid medium to remove lipids, a second near/supercritical fluid to remove nucleic acids (e.g. with the near/supercritical fluid mixed with a nucleic acid solubilizing medium as identified above), and with a third near/supercritical fluid to sterilize the ECM material (e.g.
  • Such sequential treatments with near/supercritical fluid mediums of differing compositions and function can be conducted sequentially in batch mode, or can be conducted in a continuous flow system in which a near/supercritical fluid is continuously passed through a chamber containing the ECM material and the composition of the near/supercritical fluid is changed over time by introducing the differing additives at different times in advance of the chamber.
  • the near/supercritical fluid can include substances to be added to the ECM material.
  • substances to be added can be soluble in, or dispersed or suspended in, the near/supercritical fluid.
  • the additive substances Upon contact of the near/supercritical fluid with the ECM material, the additive substances are incorporated in the ECM material. Upon separation of the near/supercritical fluid from the ECM material, amounts of the additive substances remain incorporated in the ECM material.
  • a variety of additive substances can be used, alone or in combination.
  • Illustrative additive substances include, for example, physiologically or pharmacologically active substances that act locally or systemically in a subject in which the ECM material is implanted. These substances may include antiviricides, antimicrobials and/or antibiotics such as erythromycin, bacitracin, neomycin, penicillin, polymycin B, tetracyclines, biomycin, Chloromycetin, and streptomycins, cefazolin, ampicillin, azactam, tobramycin, clindamycin, gentamycin, rifampin, minocycline, silver colloids or salts, etc.; biocidal/biostatic sugars such as dextran, glucose, etc.; amino acids; peptides; vitamins; inorganic elements; co-factors for protein synthesis; hormones; enzymes such as alkaline phosphatase, collagenase, peptidases, oxidases, etc.; angiogenic agents and polymeric carriers containing such agents; antigenic
  • TGF-beta insulin-like growth factors
  • IGF-1 insulin-like growth factors
  • IGF-2 platelet derived growth factors
  • PDGF platelet derived growth factors
  • FGF, BFGF, etc. fibroblast growth factors
  • PDLGF periodontal ligament chemotactic factor
  • GDF growth and differentiation factors
  • hedgehog family of proteins protein receptor molecules; small peptides derived from growth factors above; bone promoters; cytokines; somatotropin; bone digesters; antitumor agents; cellular attractants and attachment agents; immunosuppressants; permeation enhancers, e.g., fatty acid esters such as laureate, myristate and stearate monoesters of polyethylene glycol, enamine derivatives, alpha-keto aldehydes, etc.; nucleic acids; or mixtures including two, three or more of these additives.
  • fatty acid esters such as laureate, myristate and stearate monoesters of polyethylene
  • a drug, growth factor, or other additive substance to be incorporated into the ECM material can be water-insoluble.
  • Water-insoluble refers to substances that are either totally insoluble in water or are so poorly soluble in water that preparing an aqueous solution of the substance is practically impossible.
  • the water-insoluble substance will have that have a solubility in water at 25 of less than 0.5% by weight. The water-insoluble additive can nonetheless be solvated in the near/supercritical fluid used to treat the ECM material.
  • the near/supercritical fluid is or comprises near/supercritical carbon dioxide, and the additive substance is soluble therein.
  • the near/supercritical fluid treatment increases the range of modified, bioactive ECM materials available for medical and other applications, while providing the potential for otherwise retaining native bioactivity and mechanical properties of the ECM materials.
  • non-native bioactive components such as those synthetically produced by recombinant technology or other methods, may be incorporated into the ECM material using near/supercritical fluid processing.
  • the non-native bioactive components may be naturally-derived or recombinantly produced proteins that correspond to those natively occurring in the ECM tissue, but potentially of a different species (e.g. human proteins applied to collagenous ECMs from other animals, such as pigs).
  • the non-native bioactive components may also be drug substances such as any of those pharmacologically active substances disclosed hereinabove.
  • a substance that is solvated in the near/supercritical fluid can be precipitated from the fluid so as to be entrained or incorporated into the ECM material. This can be accomplished by adjusting the conditions of the near/supercritical fluid to reduce its solvating power for the additive substance(s). Such reduction can be achieved by reducing the pressure and/or temperature of the fluid, for instance by adjusting pressure and/or temperature to convert a supercritical fluid to a non-supercritical fluid (e.g. liquid), and/or by adding other liquids or fluids to the treatment medium to decrease its overall solvating power for the additive substance(s) in use.
  • a non-supercritical fluid e.g. liquid
  • the solvating power of the near/supercritical fluid for the substance(s) can remain unchanged, and the fluid can simply be removed, such as by evaporation, to leave amounts of the additives (e.g. as a precipitate, gel or liquid) incorporated in the ECM material.
  • the additive can for example be associated with the material through specific or non-specific interactions, or covalent or noncovalent interactions.
  • specific interactions include those between a ligand and a receptor, an epitope and an antibody, etc.
  • nonspecific interactions include hydrophobic interactions, electrostatic interactions, magnetic interactions, dipole interactions, van der Waals interactions, hydrogen bonding, etc.
  • the additive is attached to the ECM material using a linker so that the additive is free to associate with its receptor or site of action in vivo. In other embodiments the additive is either covalently or non-covalently attached to the tissue.
  • the additive may be attached to a chemical compound such as a peptide that is recognized by the tissue.
  • the additive is attached to an antibody, or fragment thereof, that recognizes an epitope found within the tissue.
  • An additive may be provided within the tissue in a sustained release format.
  • the additive may be encapsulated or otherwise incorporated within particles such as biodegradable nanospheres, microspheres, or the like.
  • the ECM material can be processed in a number of additional ways before and/or after the near/supercritical fluid treatment.
  • the ECM material can be treated with a detergent medium, DNA-solubilizing, lipid- solubilizing and/or disinfecting agent prior to or after treatment with the near/supercritical fluid.
  • the ECM material will be treated with a detergent solution, such as an ionic or nonionic detergent solution, and preferably a mild detergent solution.
  • a detergent solution such as an ionic or nonionic detergent solution, and preferably a mild detergent solution.
  • a low concentration of detergent enables retention of a substantial level of desired native components of the ECM material, such as those as noted above.
  • the ECM material will be treated with an aqueous solution of sodium dodecyl sulfate (SDS) or another ionic or nonionic detergent at a detergent concentration of about 0.05% to about 1 %, more preferably about 0.05% to about 0.3%. This treatment can be for a period of time effective to disrupt cell and nuclear membranes in the ECM material and to reduce the immunoglobulin (e.g.
  • a final ECM material product of the invention can have a native IgA content of no greater than about 20 ug/g.
  • a final ECM material of the invention can have a native IgA content of no greater than 15 ⁇ 9/9, no greater than 10 ⁇ 9 ⁇ 3, or even no greater than 5 ⁇ g/g.
  • the processed ECM material includes essentially no native IgA.
  • essentially no IgA is meant that the isolated ECM material includes IgA below detectable levels.
  • Means for detecting IgA are well known in the art and include, for example, enzyme- linked immunosorbent assay (ELISA). It will be understood in this regard that ECM materials obtained from different sources may have differing immunoglobulins that predominate in the tissue. It is expected that the processing techniques disclosed herein will be effective to reduce the content of ECM materials in other immunoglobulins, including those that predominate in the source tissue. Accordingly, other aspects of the invention relate to final ECM materials that have substantially reduced levels (e.g. less than about 20 ⁇ g/g) of (i) the predominant immunoglobulin in the source tissue, or (ii) the total immunoglobulin content (the sum of all immunoglobulins in the tissue).
  • the ECM material can be contacted with other agents that participate in achieving a desired ECM component profile, either before or after the near/supercritical fluid processing.
  • the ECM material can be treated with an aqueous medium, preferably basic, in which DNA is soluble.
  • aqueous medium preferably basic, in which DNA is soluble.
  • the basic aqueous medium can include a buffer, desirably a biocompatible buffer such as tris(hydroxymethyl)aminomethane (TRIS), and/or a chelating agent such as ethylene diamine tetraacetic acid (EDTA).
  • TMS tris(hydroxymethyl)aminomethane
  • EDTA ethylene diamine tetraacetic acid
  • the nucleic acid solubilizing medium is a TRIS-borate-EDTA (TBE) buffer solution.
  • the nucleic acid solubilizing medium is a solution of ammonium hydroxide. This treatment with a DNA solubilizing medium can be for a period of time effective to reduce the DNA content of the ECM material, typically in the range of about 0.1 hour to about 10 hours, more typically in the range of about 0.5 hours to about 2 hours.
  • methods of preparing ECM materials can involve treatment with a liquid medium that results in a substantial reduction of the level of lipid components of the ECM material, either before or after the near/supercritical fluid processing.
  • the native lipid content of a final ECM material product can be reduced to no greater than about 4% in certain embodiments.
  • a preparative process that involves a step of treating the ECM material with a liquid organic solvent in which the lipids are soluble.
  • Suitable such organic solvents include for example water-miscible solvents, including polar organic solvents. These include low molecular weight (e.g. C1 to C4) alcohols, e.g.
  • the processed ECM material will be processed to have a native lipid content no greater than about 3%, or no greater than about 2.5%.
  • This treatment with a lipid-removing medium can be for a period of time effective to reduce the lipid content of the ECM material, typically in the range of about 0.1 hour to about 1 0 hours, more typically in the range of about 0.1 hours to about 1 hours. In certain embodiments, multiple (two or more) such treatments will be conducted.
  • treatment with the lipid-reducing medium as discussed above can be carried out before or after treatment with a detergent medium and/or aqueous (preferably basic) DNA-reducing medium as discussed above.
  • treatment with the lipid-reducing medium will occur before treatment with the detergent medium and/or the aqueous (preferably basic) medium.
  • the near/supercritical fluid processing can also serve to reduce lipid content in the ECM material, alone or combined with a separate, non-near/supercritical fluid treatment regimen.
  • lipid- reducing organic solvents such as those mentioned above, e.g. methanol, ethanol, isopropanol, butanol, acetone, chloroform, and the like, can optionally be used as co-solvents in a near/supercritical fluid to aid in lipid extraction and/or for other purposes.
  • the ECM material can also optionally be treated with a disinfecting solution, before or after the near/supercritical fluid processing.
  • Preferred disinfecting agents are oxidizing agents such as peroxy compounds, preferably organic peroxy compounds, and more preferably peracids.
  • peracid compounds that can be used, these include peracetic acid, perpropioic acid, or perbenzoic acid.
  • Peracetic acid is the most preferred disinfecting agent for purposes of the present invention.
  • Such disinfecting agents are desirably used in a liquid medium, preferably a solution, having a pH of about 1 .5 to about 10, more preferably a pH of about 2 to about 6, and most preferably a pH of about 2 to about 4.
  • the disinfecting agent will generally be used under conditions and for a period of time which provide the recovery of purified ECM materials, preferably exhibiting a bioburden of essentially zero and/or essential freedom from pyrogens.
  • Certain desirable disinfecting treatments involve immersing the ECM material (e.g. by submersing or showering) in a liquid medium containing the disinfecting agent for a period of at least about 5 minutes, typically in the range of about 5 minutes to about 40 hours, and more typically in the range of about 0.5 hours to about 5 hours.
  • peracetic acid is desirably diluted into about a 2% to about 50% by volume of alcohol solution, preferably ethanol.
  • the concentration of the peracetic acid may range, for instance, from about 0.05% by volume to about 1 .0% by volume. Most preferably, the concentration of the peracetic acid is from about 0.1 % to about 0.3% by volume. When hydrogen peroxide is used, the concentration can range from about 0.05% to about 30% by volume. More desirably the hydrogen peroxide concentration is from about 1 % to about 10% by volume, and most preferably from about 2% to about 5% by volume.
  • the solution may or may not be buffered to a pH from about 5 to about 9, with more preferred pH's being from about 6 to about 7.5. These concentrations of hydrogen peroxide can be diluted in water or in an aqueous solution of about 2% to about 50% by volume of alcohol, most preferably ethanol.
  • ECM material also can be rinsed at various stages throughout its preparation (e.g., with tap water, high purity water or buffer) so as to remove introduced chemical residues that remain in or on the material.
  • Treatments such as those described herein and/or other chemical and/or mechanical treatments, will decellularize the ECM tissue, desirably resulting in a processed ECM tissue material that is decellularized, and more preferably that is substantially devoid of cells and cell components.
  • a processed ECM material can be used in an acellular form, or can be subsequently used to culture cells for studies conducted entirely in vitro, or be cultured with or otherwise seeded with cells, including for example stem cells, prior to implantation in a patient.
  • Multi-laminate constructs having from 1 to about 8 layers of the isolated ECM material will be typical.
  • the layers can be fused or bonded to one another using any suitable technique, including for example dehydrating the layers in contact with one another (e.g. by lyophilization or vacuum pressing) and/or with the use of chemical crosslinking agents to aid in bonding the layers to one another through covalent linkages.
  • Such constructs can be prepared before after near/supercritical fluid processing as described herein.
  • ECM materials of the invention can be used in a wide variety of medical indications, including for example in wound care, soft tissue support (e.g. hernia repair), soft tissue defect, and bone repair applications.
  • the ECM material can be used as a solid device (e.g. a sheet-form device or plug) or as a fluidized material such as a suspension of ECM material particles and/or a gel formed from a digest of the ECM material.
  • the final product ECM material of the invention can be packaged or otherwise stored in a dehydrated or hydrated state.
  • Dehydration of the ECM material can be achieved by any means known in the art. In certain embodiments, dehydration is accomplished by either lyophilization or vacuum pressing, although other techniques, for example air drying, can also be used. In certain embodiments, the near/supercritical fluid processing will result in a dried product which can then be packaged in such state. When stored in a dry state, it will often be desirable to rehydrate the processed ECM material prior to use. In this regard, any suitable wetting medium can be used to rehydrate the medical material, including as examples water or buffered saline solutions.
  • SIS was prepared from a segment of whole small intestine from a mature adult hog. The intestine was rinsed with water, and then treated in a 0.2 percent by volume peracetic acid in a 5 percent by volume aqueous ethanol solution (pH approximately 2.6) for a period of two hours with agitation. The high-strength ECM sheet including the submucosa layer (SIS) was then delaminated from the remainder of the intestinal tissue in a disinfected casing machine. The SIS was then rinsed with sterile water. The wet SIS was arranged into 4-SIS-layer stacks, all air bubbles smoothed from the stacks, and lyophilized. The lyophilization of the stacked SIS resulted in 4-ply lyophilized laminate sheets.
  • Test samples Six 4-ply SIS sheets were initially provided from the above SIS lot, sized 7 cm X 20 cm. Each 4-ply sheet was cut in half to provide two 7 cm x 10 cm sheets and labeled as Test samples or sheet matched Controls. Pretreatment weights for the Test samples were recorded after stabilization for greater than 18 hours in a desiccator. The Test samples were exposed, with agitation, to supercritical C0 2 at 4000 psi and 40 5 C for 2 hours followed by gradual dissipation of pressure and then stabilization of the samples for greater than 18 hours in a desiccator. Final weight of the Test samples was recorded and samples were then subjected to mechanical and biochemical component testing.
  • test and Control sheet samples of Test and Control sheet were taken and assessed for the presence of FGF-2, sGAG, IgA and lipid.
  • content values weights were recorded and all calculations were based on content divided by the initial weight of the sample.
  • the supercritical C0 2 treatment did not significantly alter the tensile strength of the SIS Test samples as compared to the Controls.
  • the ultimate tensile force at failure for the Test samples was 12.8 ⁇ 2.5 Newtons, whereas that for the Control samples was 12.3 ⁇ 2.3 Newtons.
  • the FGF-2 content for the Control samples was 1 1 1 ,000 ⁇ 1 1 ,000 picogram/gram and for the treated Test samples was 123,000 ⁇ 14,000 picogram/gram.
  • the sGAG content for the Control samples was 3.6 ⁇ 0.72 ⁇ g/g and for the treated Test samples was 4.1 1 ⁇ 0.08 ⁇ 9/9.
  • the IgA content of the SIS Test samples was not reduced by the treatment.
  • the IgA content for the Control samples was 21 .6 ⁇ 3.0 ng/mg and for the treated Test samples was 34.4 ⁇ 5.5 ng/mg.
  • the slight increase in the observed FGF-2, sGAG and IgA levels for the treated Test samples is likely due at least in part to the decrease in overall weight of the samples caused by the treatment.
  • Cell nucleus remnants, as assessed using fluorescent staining and microscopy, were not significantly altered in the treated Test samples versus Controls.
  • the lipid content of the treated Test samples was significantly reduced as compared to the Controls.
  • the lipid level for the Control samples was 9.3 ⁇ 1 .9% by weight and for the treated Test samples was 1 .6 ⁇ 0.4% by weight.

Abstract

L'invention porte sur des procédés de préparation de matériaux de matrice extracellulaire à l'aide d'un traitement avec un fluide dans des conditions dans lesquelles le fluide est au moins sensiblement supercritique. Les matériaux préparés de matrice extracellulaire préférés conservent de façon bénéfique des molécules bioactives endogènes et/ou des propriétés mécaniques natives bénéfiques même après un traitement avec le fluide. L'invention porte également sur des matériaux qui peuvent être préparés par ces procédés, et sur des utilisations de ces matériaux.
PCT/US2010/048223 2009-09-09 2010-09-09 Fabrication de produits de matrice extracellulaire à l'aide de fluides supercritiques ou quasi-supercritiques WO2011031827A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24073209P 2009-09-09 2009-09-09
US61/240,732 2009-09-09

Publications (2)

Publication Number Publication Date
WO2011031827A2 true WO2011031827A2 (fr) 2011-03-17
WO2011031827A3 WO2011031827A3 (fr) 2011-06-03

Family

ID=43513896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/048223 WO2011031827A2 (fr) 2009-09-09 2010-09-09 Fabrication de produits de matrice extracellulaire à l'aide de fluides supercritiques ou quasi-supercritiques

Country Status (1)

Country Link
WO (1) WO2011031827A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166538A1 (fr) 2011-05-27 2012-12-06 Cormatrix Cardiovascular, Inc. Compositions de matrice extracellulaire stérilisées, acellulaires, et leurs procédés de fabrication
WO2017118266A1 (fr) * 2016-01-08 2017-07-13 Chen Shing-Jye Cornées acellulaires, procédés de production de celles-ci et utilisations de celles-ci
CN107164298A (zh) * 2017-06-02 2017-09-15 广州新诚生物科技有限公司 超临界流体技术制备软组织去细胞基质的方法
CN108025111A (zh) * 2015-08-11 2018-05-11 亚果生医股份有限公司 去细胞软骨移植物的制备方法与用途
CN109550082A (zh) * 2018-11-30 2019-04-02 广州新诚生物科技有限公司 一种脱细胞基质凝胶的制备方法
EP2752192B1 (fr) * 2011-09-02 2019-06-26 Adeka Corporation Procédé de préparation d'un produit tissulaire décellularisé, et greffon doté d'un produit tissulaire décellularisé
WO2020264385A1 (fr) * 2019-06-28 2020-12-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Systèmes et procédés biologiques sensibles autonomes
US10993802B2 (en) * 2013-09-11 2021-05-04 Cormatrix Cardiovascular, Inc. Systems, apparatus and methods for sealing perivalvular leaks
CN113368313A (zh) * 2021-06-10 2021-09-10 吾奇生物医疗科技(江苏)有限公司 一种生物膜的制备方法及其产品和应用
WO2022116464A1 (fr) * 2020-12-03 2022-06-09 广东省科学院健康医学研究所 Matrice acellulaire et son procédé de préparation, et échafaudage de réparation osseuse
WO2023039833A1 (fr) * 2021-09-17 2023-03-23 谢达仁 Utilisation de particules de collagène pour favoriser la formation de follicules pileux ou une angiogenèse

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361552A (en) 1980-09-26 1982-11-30 Board Of Regents, The University Of Texas System Wound dressing
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US6099567A (en) 1996-12-10 2000-08-08 Purdue Research Foundation Stomach submucosa derived tissue graft
US6206931B1 (en) 1996-08-23 2001-03-27 Cook Incorporated Graft prosthesis materials
US6379710B1 (en) 1996-12-10 2002-04-30 Purdue Research Foundation Biomaterial derived from vertebrate liver tissue
WO2003002165A1 (fr) 2001-06-28 2003-01-09 Cook Biotech Incorporated Dispositifs prothetiques de greffe comprenant du collagene de capsules renales
US6576618B1 (en) 1999-06-22 2003-06-10 Research Development Foundation Methods to enhance wound healing and enhanced wound coverage material

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699408B1 (fr) * 1992-12-21 1995-03-24 Bioland Procédé de traitement de tissus osseux et biomatériaux implantables correspondants.
US20060127442A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles
US20100323440A1 (en) * 2007-06-12 2010-12-23 Musculoskeletal Transplant Foundation Process for sterilizing acellular soft tissue under pressure

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361552A (en) 1980-09-26 1982-11-30 Board Of Regents, The University Of Texas System Wound dressing
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US6206931B1 (en) 1996-08-23 2001-03-27 Cook Incorporated Graft prosthesis materials
US6099567A (en) 1996-12-10 2000-08-08 Purdue Research Foundation Stomach submucosa derived tissue graft
US6379710B1 (en) 1996-12-10 2002-04-30 Purdue Research Foundation Biomaterial derived from vertebrate liver tissue
US6576618B1 (en) 1999-06-22 2003-06-10 Research Development Foundation Methods to enhance wound healing and enhanced wound coverage material
WO2003002165A1 (fr) 2001-06-28 2003-01-09 Cook Biotech Incorporated Dispositifs prothetiques de greffe comprenant du collagene de capsules renales

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. HEESCHEN, NATURE MEDICINE, vol. 7, no. 7, 2001, pages 833 - 839
C. JOHNSON ET AL., CIRCULATION RESEARCH, vol. 94, no. 2, 2004, pages 262 - 268

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166538A1 (fr) 2011-05-27 2012-12-06 Cormatrix Cardiovascular, Inc. Compositions de matrice extracellulaire stérilisées, acellulaires, et leurs procédés de fabrication
EP2714099A1 (fr) * 2011-05-27 2014-04-09 Cormatrix Cardiovascular, Inc. Compositions de matrice extracellulaire stérilisées, acellulaires, et leurs procédés de fabrication
JP2014519906A (ja) * 2011-05-27 2014-08-21 コーマトリックス カーディオバスキュラー， インコーポレイテッド 滅菌された無細胞の細胞外マトリックス組成物及びその作製方法
EP2714099A4 (fr) * 2011-05-27 2014-11-19 Cormatrix Cardiovascular Inc Compositions de matrice extracellulaire stérilisées, acellulaires, et leurs procédés de fabrication
EP2752192B1 (fr) * 2011-09-02 2019-06-26 Adeka Corporation Procédé de préparation d'un produit tissulaire décellularisé, et greffon doté d'un produit tissulaire décellularisé
US10993802B2 (en) * 2013-09-11 2021-05-04 Cormatrix Cardiovascular, Inc. Systems, apparatus and methods for sealing perivalvular leaks
CN108025111A (zh) * 2015-08-11 2018-05-11 亚果生医股份有限公司 去细胞软骨移植物的制备方法与用途
WO2017118266A1 (fr) * 2016-01-08 2017-07-13 Chen Shing-Jye Cornées acellulaires, procédés de production de celles-ci et utilisations de celles-ci
CN107164298A (zh) * 2017-06-02 2017-09-15 广州新诚生物科技有限公司 超临界流体技术制备软组织去细胞基质的方法
CN109550082A (zh) * 2018-11-30 2019-04-02 广州新诚生物科技有限公司 一种脱细胞基质凝胶的制备方法
WO2020264385A1 (fr) * 2019-06-28 2020-12-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Systèmes et procédés biologiques sensibles autonomes
WO2022116464A1 (fr) * 2020-12-03 2022-06-09 广东省科学院健康医学研究所 Matrice acellulaire et son procédé de préparation, et échafaudage de réparation osseuse
CN113368313A (zh) * 2021-06-10 2021-09-10 吾奇生物医疗科技(江苏)有限公司 一种生物膜的制备方法及其产品和应用
WO2023039833A1 (fr) * 2021-09-17 2023-03-23 谢达仁 Utilisation de particules de collagène pour favoriser la formation de follicules pileux ou une angiogenèse

Also Published As

Publication number Publication date
WO2011031827A3 (fr) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2011031827A2 (fr) Fabrication de produits de matrice extracellulaire à l'aide de fluides supercritiques ou quasi-supercritiques
EP2079490B1 (fr) Materiaux de matrice extracellulaire traites presentant des profils de composants ameliores
US8591930B2 (en) Growth factor modified extracellular matrix material preparation and methods for preparation and use thereof
US9138445B2 (en) Medical graft materials with adherent extracellular matrix fibrous mass
US9138444B2 (en) Dried collagenous biomaterial medical device
US20170100509A1 (en) Method for shaping tissue matrices
EP2310061B1 (fr) Matériau de matrice extracellulaire isolé comprenant un fascia sous-séreux
US20030206860A1 (en) Radiopaque implantable collagenous biomaterial device
US8557277B2 (en) Medical products including modified extracellular matrix materials
US20100266654A1 (en) Medical composition including an extracellular matrix particulate
US20110236949A1 (en) Methods for Processing Biological Tissues
AU2015236088A1 (en) Extracellular matrix grafts loaded with exogenous factors
Raghuvanshi et al. Preparation and characterization of caprine forestomach matrix (CFM) for biomedical application
WO2010088678A2 (fr) Produits de billes médicales
WO2010078478A1 (fr) Adjuvants de tissu et produits médicaux les comprenant
CN115551565A (zh) 高强度胶原组合物及使用方法
WO2019056252A1 (fr) Matériau de matrice extracellulaire possédant une activité biologique élevée, procédé de préparation s'y rapportant et application associée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10754834

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10754834

Country of ref document: EP

Kind code of ref document: A2